Healthcare, Pharma & Life Sciences

Gargle Adds AI Search Optimization to Dental SEO Offering

Lehi, Utah – September 08, 2026 -- Gargle, Inc. has expanded its dental marketing SEO product to include Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO), addressing a shift in how patients search for dental care through AI tools and voice assistants.

Gargle integrates AEO and GEO directly into its existing SEO service without added fees

The dental marketing agency confirmed that existing clients will not need to purchase separate software or add another vendor to access the new capabilities. Jeff Richins, President of Gargle, said the company incorporated the strategies into its current SEO work to give clients added value while preparing for changes in search behavior.

Codoxo Wins 2026 Fierce AI Innovation Award for Payment Integrity

Image
Codoxo Wins 2026 Fierce AI Innovation Award for Payment Integrity

Duluth, Ga. – September 08, 2026 -- Codoxo's Point Zero Payment Integrity solution has won the "AI Innovation in Regulatory & Compliance" category at the 2026 Fierce AI Innovation Awards, recognizing its approach to preventing healthcare payment errors before claims are created.

Point Zero delivered over $20 million in first-year savings for a leading health plan

One leading health plan using Point Zero achieved more than $20 million in first-year savings, exceeding internal projections by 25%, while simultaneously improving provider engagement and coding accuracy. Across its Point Zero deployments, Codoxo reports health plans have realized $12 to $16 in per-member-per-year savings and cut overpayments by as much as 40%.

Akeso's Ivonescimab Beats Pembrolizumab on Survival in Phase III NSCLC Trial

Hong Kong – September 08, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Ivonescimab clears key secondary survival endpoint against Keytruda

The HARMONi-2 (AK112-303) study is a randomized, double-blind, multicenter registrational trial testing ivonescimab against pembrolizumab as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at a TPS of 1% or higher. Detailed interim overall survival data will be presented at an upcoming international medical conference and published in a peer-reviewed journal.

Nanochon Treats First Patient in Chondrograft Knee Cartilage Trial

Image
Nanochon Treats First Patient in Chondrograft Knee Cartilage Trial

Baltimore – September 08, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Drs. Osorio and Tufiño perform first Chondrograft implant procedure in Panama

Dr. Juan Osorio, the study's Principal Investigator, and Dr. Emilio Tufiño, both specialists in regenerative sports medicine, carried out the bone-sparing, minimally invasive procedure. Dr. Tufiño noted the dedicated instrumentation set made the operation simple and efficient.

Amgen Executives to Present at Wells Fargo Healthcare Conference

Image
Amgen Executives to Present at Wells Fargo Healthcare Conference

Thousand Oaks, Calif. – September 08, 2026 -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 08, 2026.

Amgen's CFO and top medical and marketing executives will address investors

Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access, will represent Amgen at the conference.

Webcast access will be public and archived for 90 days

The presentation will be webcast live and made available to media, investors and the general public via Amgen's website under the Investors section. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will remain archived for replay for at least 90 days following the event.

Helfie AI Names John Rego CFO After $10B in Capital Raises

Image
Helfie AI Names John Rego CFO After $10B in Capital Raises

Melbourne, Australia – September 08, 2026 -- Helfie AI has appointed John Rego as Chief Financial Officer, bringing a track record of raising more than $10 billion in capital and closing over two dozen M&A transactions across six public and private companies.

Rego joins Helfie from Wide Open West following the US broadband provider's 2026 sale

Rego served as CFO of Wide Open West (NYSE: WOW) from 2020 until the company was sold in 2026. The appointment gives Helfie AI, a Melbourne-based AI-powered preventative healthcare platform, a finance chief with direct experience managing a company through to a market exit.

Baystate Health Expands UMass Sponsorship With On-Field Branding

Image
Baystate Health Expands UMass Sponsorship With On-Field Branding

Amherst, Mass. – September 08, 2026 -- Baystate Health will place its logo on both 25-yard lines at McGuirk Alumni Stadium starting with the 2026 UMass football season, marking the first time a brand logo has appeared on the field's gridiron in the stadium's history since 1965. The move expands a multi-year partnership between UMass Athletics, Baystate Health and Learfield's UMass Sports Properties, deepening a sponsorship relationship that has run for more than a decade.

Pharma Deutschland Presses Berlin on AMNOG Reform Amid Rebate Hikes

Image
Pharma Deutschland Presses Berlin on AMNOG Reform Amid Rebate Hikes

Berlin – September 08, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.

Federal Ministry convenes stakeholders for September 3 dialogue

The Federal Ministry of Health has invited industry representatives to an in-depth discussion on Thursday, September 08, 2026, focused on harmonizing Germany's drug pricing and assessment framework. Pharma Deutschland, which represents roughly 400 member companies employing about 80,000 people in Germany, said it backs the continuation of the Pharma- und Medizintechnik Dialog but insists selective bureaucratic fixes cannot offset broader damage from recent legislation.

Allergan Aesthetics Report: 12,000 Consumers Shift to Layered Treatment Plans

North Chicago, Ill. – September 08, 2026 -- Allergan Aesthetics, an AbbVie company, has released a global study of more than 12,000 beauty-involved consumers across nine markets showing a decisive shift away from one-time aesthetic procedures toward personalized, long-term treatment plans.

Global survey data points to a structural change in patient demand patterns

The Layered Beauty: The New Aesthetic Mindset report, based on the 12,000-consumer dataset combined with practitioner input and regional analysis, finds patients increasingly expect multimodal treatment strategies that evolve with their goals and life stages rather than single-session fixes.

Skin quality now anchors broader aesthetic and wellness spending

Respondents identified skin quality as the foundation of aesthetic care, integrating treatments into wider beauty and wellness routines rather than treating them as isolated interventions.

OrthoArizona Opens $25M Glendale Orthopedic Campus

Image
OrthoArizona Opens $25M Glendale Orthopedic Campus

Glendale, Ariz. – September 08, 2026 -- OrthoArizona has opened a $25 million, 50,000-square-foot orthopedic center at 9070 W. Glendale Ave., adjacent to Westgate and State Farm Stadium, combining surgery, imaging and therapy under one roof.

New campus consolidates full care pathway in a single building

The Glendale facility houses comprehensive musculoskeletal care, an on-site ambulatory surgery center, physical therapy and advanced imaging, including MRI, allowing patients to move from first visit to full recovery at one location. Dr. Rajan Bhatt, chief executive officer of OrthoArizona, said the group has grown since 1994 by staying close to the communities it serves, calling Glendale the clearest expression of that strategy.